Varian Announces CE Mark for Embozene in Genicular Artery Embolisation, Expanding Treatment for Knee Osteoarthritis

(NYSE:VAR) PALO ALTO, Calif.--(BUSINESS WIRE)--Varian, a Siemens Healthineers company, announced today that its Embozene microspheres have received CE Marking for Genicular Artery Embolisation (GAE) for knee osteoarthritis. This regulatory milestone makes Embozene the first—and only—embolic agent to be CE Marked specifically for GAE, a minimally invasive procedure intended to target inflammation and help relieve pain in patients with knee osteoarthritis. Knee osteoarthritis is widespread, with a reported